Yahoo Finance • yesterday
[Journey of Distinction - Gradient Spheres Tapering Along Steps to a Singular Summit] J Studios/DigitalVision via Getty Images Deutsche Bank’s research team selected their top investment ideas to hold over the next 12 months, with new pic... Full story
Yahoo Finance • 7 days ago
Alkermes' (ALKS) 7% stock decline following results of its phase 2 study of alixorexton in patients PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 7 days ago
[Wall Street New York stock exchange stock market] alexsl Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]) shares spiked on Friday after RBC Capital Markets upgraded the Irish biotech to Outperform from Sector Perform, citing... Full story
Yahoo Finance • 7 days ago
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Rothschild & Co Redburn upgraded Kenvue... Full story
Yahoo Finance • 15 days ago
Alkermes (NASDAQ:ALKS) is one of the best beginner stocks to buy, according to analysts. On September 9, HC Wainwright reiterated a ‘Neutral’ rating on the stock and a $46 price target. The stance follows the company’s positive results fro... Full story
Yahoo Finance • 21 days ago
* Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]), effective September 15, 2025. * Reed previously served as CFO of Omega Therapeutics and Aldeyra Therapeutics... Full story
Yahoo Finance • 25 days ago
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Alkermes plc (Symbol: ALKS), where a total of 8,976 contracts have traded so far, representing approximately 897,600 underlying sh... Full story
Yahoo Finance • 2 months ago
ALKERMES PLC (NASDAQ:ALKS [https://www.chartmill.com/stock/quote/ALKS]) has been recognized as a possible choice for value investors using a "Decent Value" screening method. This approach targets stocks with solid fundamental valuations, s... Full story
Yahoo Finance • 2 months ago
ALKERMES PLC (NASDAQ:ALKS [https://www.chartmill.com/stock/quote/ALKS]) reported second-quarter 2025 financial results that exceeded analyst expectations, driving a notable pre-market rally. The biopharmaceutical company posted revenue of... Full story
Yahoo Finance • 2 months ago
Investing.com - Alkermes Plc (NASDAQ: ALKS) reported second quarter EPS of $0.52, $0.16 better than the analyst estimate of $0.36. Revenue for the quarter came in at $390.7M versus the consensus estimate of $347.16M. Alkermes Plc’s stoc... Full story
Yahoo Finance • 2 months ago
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.24% this morning, extending yesterday’s gains, while investors shift their focus from recent U.S. trade deals to economic data, a n... Full story
Yahoo Finance • 2 months ago
Major earnings expected before the bell on Tuesday include: * The Boeing Company (BA [https://seekingalpha.com/symbol/BA]) * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * The Procter & Gamble Company (PG [https://s... Full story
Yahoo Finance • 2 months ago
* Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. * The consensus EPS Estimate is $0.38 [https://seekingalpha.com/symbol/ALKS/earning... Full story
Yahoo Finance • 2 months ago
Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
Check out the companies making the biggest moves midday: Bruker — The lab instrument and tools maker shed 12% after the company issued weaker-than-expected guidance for the second quarter. The company expects to earn between 32 and 34 cent... Full story
Yahoo Finance • 2 months ago
Investing.com - Alkermes (NASDAQ:ALKS) shares fell Monday after BofA Securities maintained its Neutral rating and $35.00 price target following the company’s Phase 2 trial results for its narcolepsy treatment. According to InvestingPro dat... Full story
Yahoo Finance • 2 months ago
DUBLIN - Alkermes plc (NASDAQ:ALKS), a pharmaceutical company with a market capitalization of $4.8 billion and an impressive 84% gross profit margin, announced Monday that its experimental narcolepsy treatment alixorexton demonstrated stat... Full story
Yahoo Finance • 3 months ago
DUBLIN - Investment management firm BlackRock (NYSE:BLK), Inc. has increased its stake in biopharmaceutical company Alkermes (NASDAQ:ALKS) PLC, according to a disclosure filed Thursday with the Irish Takeover Panel. BlackRock acquired 127... Full story
Yahoo Finance • 3 months ago
[The office building of CVS Health at its Corporate Headquarters at 1 CVS Dr, Woonsocket, RI, USA] JHVEPhoto Deutsche Bank this week updated its Fresh Money Quarterly list, spotlighting top investment ideas to hold over the next year in d... Full story
Yahoo Finance • 4 months ago
The S&P 500 Index ($SPX) (SPY) Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.70%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.00%. June E-mini S&P futures (ESM25) are down -0.86%, and J... Full story